Schafer C Boeder (Schafer Boeder)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 18

Top Topics

Hyaluronic Acid

Patient Satisfaction

Top Venues

Diabetes therapy : research, treatment and education of diabetes and related disorders

Diabetes technology & therapeutics

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Robert L Thomas, Schafer C Boeder, Vala Hamidi, Erin R Giovannetti, Justin M Gregory, Jeremy H Pettus
Continuous Glucose Monitoring Time Below Range Predicts Impaired Epinephrine Response to Hypoglycemia in Patients With Type 1 Diabetes. Diabetes care 47 (5) (2024)
Schafer C Boeder, Robert L Thomas, Melissa J Le Roux, Erin R Giovannetti, Justin M Gregory, Jeremy H Pettus
Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial. Diabetes care (2024)
Schafer C Boeder, Michael J Davies, Janet B McGill, Richard Pratley, Manon Girard, Phillip Banks, Jeremy Pettus, Satish Garg
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin. Diabetes technology & therapeutics (2024)
Robert L Thomas, Schafer C Boeder, Vala Hamidi, Erin R Giovannetti, Justin M Gregory, Jeremy H Pettus
Continuous Glucose Monitoring Time Below Range Predicts Impaired Epinephrine Response to Hypoglycemia in Patients With Type 1 Diabetes. Diabetes care (2024)
Schafer C Boeder, Michael J Davies, Janet B McGill, Richard Pratley, Manon Girard, Phillip Banks, Jeremy Pettus, Satish Garg
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin. Diabetes technology & therapeutics (2024)
Robert L Thomas, Schafer C Boeder, Vala Hamidi, Erin R Giovannetti, Justin M Gregory, Jeremy H Pettus
Continuous Glucose Monitoring Time Below Range Predicts Impaired Epinephrine Response to Hypoglycemia in Patients With Type 1 Diabetes. Diabetes care 47 (5) (2024)
Robert L Thomas, Schafer C Boeder, Vala Hamidi, Erin R Giovannetti, Justin M Gregory, Jeremy H Pettus
Continuous Glucose Monitoring Time Below Range Predicts Impaired Epinephrine Response to Hypoglycemia in Patients With Type 1 Diabetes. Diabetes care (2024)
Robert L Thomas, Schafer C Boeder, Vala Hamidi, Erin R Giovannetti, Justin M Gregory, Jeremy H Pettus
Continuous Glucose Monitoring Time Below Range Predicts Impaired Epinephrine Response to Hypoglycemia in Patients With Type 1 Diabetes. Diabetes care 47 (5) (2024)
Schafer C Boeder, Michael J Davies, Janet B McGill, Richard Pratley, Manon Girard, Phillip Banks, Jeremy Pettus, Satish Garg
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin. Diabetes technology & therapeutics 26 (9) (2024)
Jeremy H Pettus, Schafer C Boeder, Mark P Christiansen, Douglas S Denham, Timothy S Bailey, Halis Kaan Akturk, Leslie J Klaff, Julio Rosenstock, Mickie H M Cheng, Bruce W Bode, Edgar D Bautista, Ren Xu, Hai Yan, Dung Thai, Satish K Garg, Samuel Klein
Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nature medicine (2023)
Schafer C Boeder, David Matamoros, Caroline Mansy
Practical Guidance for Healthcare Providers on Collaborating with People with Type 2 Diabetes: Advancing Treatment and Initiating Injectable Therapy. Diabetes therapy : research, treatment and education of diabetes and related disorders 14 (2) (2022)
Schafer C Boeder, David Matamoros, Caroline Mansy
Practical Guidance for Healthcare Providers on Collaborating with People with Type 2 Diabetes: Advancing Treatment and Initiating Injectable Therapy. Diabetes therapy : research, treatment and education of diabetes and related disorders 14 (2) (2022)
Schafer C Boeder, David Matamoros, Caroline Mansy
Practical Guidance for Healthcare Providers on Collaborating with People with Type 2 Diabetes: Advancing Treatment and Initiating Injectable Therapy. Diabetes therapy : research, treatment and education of diabetes and related disorders 14 (2) (2022)
Schafer C Boeder, David Matamoros, Caroline Mansy
Practical Guidance for Healthcare Providers on Collaborating with People with Type 2 Diabetes: Advancing Treatment and Initiating Injectable Therapy. Diabetes therapy : research, treatment and education of diabetes and related disorders 14 (2) (2022)
Schafer C Boeder, David Matamoros, Caroline Mansy
Practical Guidance for Healthcare Providers on Collaborating with People with Type 2 Diabetes: Advancing Treatment and Initiating Injectable Therapy. Diabetes therapy : research, treatment and education of diabetes and related disorders 14 (2) (2022)
Schafer C Boeder, David Matamoros, Caroline Mansy
Practical Guidance for Healthcare Providers on Collaborating with People with Type 2 Diabetes: Advancing Treatment and Initiating Injectable Therapy. Diabetes therapy : research, treatment and education of diabetes and related disorders 14 (2) (2022)
Schafer C Boeder, David Matamoros, Caroline Mansy
Practical Guidance for Healthcare Providers on Collaborating with People with Type 2 Diabetes: Advancing Treatment and Initiating Injectable Therapy. Diabetes therapy : research, treatment and education of diabetes and related disorders (2022)
Jeremy H Pettus, Schafer C Boeder, Mark P Christiansen, Douglas S Denham, Timothy S Bailey, Halis Kaan Akturk, Leslie J Klaff, Julio Rosenstock, Mickie H M Cheng, Bruce W Bode, Edgar D Bautista, Ren Xu, Hai Yan, Dung Thai, Satish K Garg, Samuel Klein
Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nature medicine 28 (10) (2022)